Patent · US Active

RNAi modulation of Aha and therapeutic uses thereof

US8114984B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignees

Alnylam Pharmaceuticals, Inc. · US
THE SCRIPPS RESEARCH INSTITUTE · US

Inventors

Rainer Constien · Kulmbach, DE
Birgit Bramlage · Ebikon, CH
Pamela Tan · Kulmbach, DE
Hans-Peter Vornlocher · Bayreuth, DE
William Balch · San Diego, US

Key dates

Filing date	Sep 7, 2010
Grant date	Feb 14, 2012
Priority date	—
Expiry date	Sep 7, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.